Adjuvant chemotherapy combined with pembrolizumab immunotherapy for primary triple-negative neuroendocrine carcinoma of the breast: a case report and literature review
Neuroendocrine breast cancer (NEBC) is an exceedingly rare malignant tumor, with primary triple-negative NEBC representing an even rarer and more aggressive subtype lacking standardized treatment guidelines. Although pembrolizumab combined with chemoth…